180 related articles for article (PubMed ID: 34521054)
21. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
[TBL] [Abstract][Full Text] [Related]
22. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
Shang X; Lin X; Manorek G; Howell SB
Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
[TBL] [Abstract][Full Text] [Related]
23. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma.
Kim CJ; Lee JW; Choi JJ; Choi HY; Park YA; Jeon HK; Sung CO; Song SY; Lee YY; Choi CH; Kim TJ; Lee JH; Kim BG; Bae DS
Eur J Cancer; 2011 Apr; 47(6):918-25. PubMed ID: 21134740
[TBL] [Abstract][Full Text] [Related]
24. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
[TBL] [Abstract][Full Text] [Related]
25. Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Li X; Pan Q; Wan X; Mao Y; Lu W; Xie X; Cheng X
BMC Cancer; 2015 Jul; 15():509. PubMed ID: 26152689
[TBL] [Abstract][Full Text] [Related]
26. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
27. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
29. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
Wang D; You D; Li L
J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
[TBL] [Abstract][Full Text] [Related]
30. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
[TBL] [Abstract][Full Text] [Related]
31. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer.
Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P
Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793
[TBL] [Abstract][Full Text] [Related]
32. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract][Full Text] [Related]
33. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
34. N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation.
Li H; Lin R; Zhang Y; Zhu Y; Huang S; Lan J; Lu N; Xie C; He S; Zhang W
Mol Cancer; 2024 Jan; 23(1):5. PubMed ID: 38184597
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
[TBL] [Abstract][Full Text] [Related]
36. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.
Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z
Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244
[TBL] [Abstract][Full Text] [Related]
37. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
39. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
[TBL] [Abstract][Full Text] [Related]
40. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
